Nektar Therapeutics (NASDAQ:NKTR)
| Market Cap | $866.38M-48.5% |
| Revenue (ttm) | $52.19M-16.6% |
| Net Income | -$177.26M-46.8% |
| EPS | -$6.46+18.5% |
| Shares Out | 28.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,017,708 |
| Open | $31.66 |
| Previous Close | $32.54 |
| Day's Range | $30.13 - $32.35 |
| 52-Week Range | $30.13 - $109.00 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | $107.20(+254.97%) |
| Earnings Date | Mar 11, 2027 |
About NKTR
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating NKTR in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 11, 2027Earnings report
$NKTR stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of NKTR by members of U.S. Congress
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Jun 21, 2018 |
| Josh GottheimerHouse / D | Purchase$1.00K – $15.00K | Jun 6, 2018 |
Recently reported changes in NKTR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NKTR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NKTR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NKTR Revenue by Segment
| Other operating costs | $19.57M | 47.67% |
| Employee costs | $18.88M | 45.97% |
| Facilities costs | $2.61M | 6.36% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NKTR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NKTR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NKTR
| VTIVanguard Morningstar Total Stock Market ETF | $33.13M |
| XBIState Street SPDR S&P Biotech ETF | $32.53M |
| IWMiShares Russell 2000 ETF | $29.39M |
| VXFVanguard Extended Market ETF | $15.12M |
| IWOiShares Russell 2000 Growth ETF | $9.46M |
| VTWOVanguard Russell 2000 ETF | $7.88M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NKTR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings miss on revenue, analyst price target cut, offset partially by clinical trial progress and narrowing losses.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| CNCR | Loncar Cancer Immunotherapy ETF | 3.37% |
| SPIT | F/m Emerald Special Situations ETF | 1.69% |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 1.58% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.83% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.51% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.48% |
| XBI | State Street SPDR S&P Biotech ETF | 0.37% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.30% |
| DMRM | DeltaShares S&P 400 Managed Risk ETF | 0.13% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.12% |
| FTKI | First Trust Small Cap BuyWrite Income ETF | 0.09% |
| JKL | iShares Morningstar Small-Cap Value ETF | 0.09% |
Weight is the stock’s share of each fund’s holdings.
